Catabasis Pharmaceuticals, Inc. reports financial results for the second quarter ended 30 June 2021 and provides a corporate update.
“We are focused on advancing the development of our lead program, QLS-215, as a differentiated and potentially the most patient-friendly treatment option for the chronic treatment of patients with HAE to prevent attacks,” says Jill C. Milne, Ph.D., CEO of Catabasis. “We anticipate that our first clinical trial with QLS-215 could demonstrate clinical proof of concept of its differentiated profile and long antibody half-life. Initial results from this trial are anticipated by the end of 2022.”
QLS-215 for the Treatment of HAE
- The vision for the lead program, QLS-215, is to develop a monoclonal antibody inhibitor of plasma kallikrein for HAE with dosing once every three months or longer and sustained inhibitory blood levels. QLS-215 has the potential to be the most patient-friendly chronic treatment option, based on the data generated to date and the existing HAE treatment landscape.
- QLS-215 is a humanized monoclonal antibody targeting plasma kallikrein that has demonstrated potent inhibition of plasma kallikrein as well as a long plasma half-life in non-human primates.
- Recent discussions with physicians and patients confirm the need for effective treatments that reduce HAE attacks as well as reduce the burden of treatment.
- Catabasis expects to file an Investigational New Drug application for QLS-215 in mid-2022 and plans to initiate a Phase 1 clinical trial with initial results anticipated by year end 2022. Catabasis expects that the results of this trial, if positive, could provide clinical proof of concept for the activity and plasma half-life improvements for QLS-215.